Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT)
Purpose: To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Ther...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Publication date: | 2021 |
| Country: | España |
| Institution: | Universidad de Navarra |
| Repository: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Language: | English |
| OAI Identifier: | oai:dadun.unav.edu:10171/115041 |
| Online Access: | https://hdl.handle.net/10171/115041 |
| Access Level: | Open access |
| Keyword: | Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90 |
| _version_ | 1878734622971396096 |
|---|---|
| author | Helmberger, T. (Thomas)|||/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 |
| author2 | Golfieri, R. (Rita)|||/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Pfammatter, T. (Thomas)|||/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Arnold, D. (Dirk)|||/items/099bd9e3-21b5-4667-b221-019be2f28370 Cianni, R. (Roberto)|||/items/44136911-1445-4958-bb06-51b0c81a263a Maleux, G. (Geert)|||/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)|||/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pellerin, O. (Olivier)|||/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)|||/items/e3405054-aec1-45e4-8aed-64763da49bc9 Jong, N. (Niels) de|||/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Bilbao, J.I. (José I.)|||/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88 |
| author2_role | author author author author author author author author author author author author author |
| author_browse | Arnold, D. (Dirk)|||/items/099bd9e3-21b5-4667-b221-019be2f28370 Bilbao, J.I. (José I.)|||/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88 Cianni, R. (Roberto)|||/items/44136911-1445-4958-bb06-51b0c81a263a Golfieri, R. (Rita)|||/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Helmberger, T. (Thomas)|||/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Jong, N. (Niels) de|||/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Maleux, G. (Geert)|||/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)|||/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Pellerin, O. (Olivier)|||/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Pfammatter, T. (Thomas)|||/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)|||/items/e3405054-aec1-45e4-8aed-64763da49bc9 |
| author_facet | Helmberger, T. (Thomas)|||/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Golfieri, R. (Rita)|||/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Pfammatter, T. (Thomas)|||/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Arnold, D. (Dirk)|||/items/099bd9e3-21b5-4667-b221-019be2f28370 Cianni, R. (Roberto)|||/items/44136911-1445-4958-bb06-51b0c81a263a Maleux, G. (Geert)|||/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)|||/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pellerin, O. (Olivier)|||/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)|||/items/e3405054-aec1-45e4-8aed-64763da49bc9 Jong, N. (Niels) de|||/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Bilbao, J.I. (José I.)|||/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88 |
| author_role | author |
| collection | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| description | Purpose: To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). Materials and methods: Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected. Results: Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE. Conclusion: In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. Level of evidence: Level 3. Trial registration: ClinicalTrials.gov NCT02305459. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_6d0bb3a1e2da2ae2be2768f541ff6a2b |
| institution | Universidad de Navarra |
| instname_str | Universidad de Navarra |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:dadun.unav.edu:10171/115041 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | Springer Nature |
| publisherStr | Springer Nature |
| reponame_str | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| spelling | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) Helmberger, T. (Thomas)|||/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Golfieri, R. (Rita)|||/items/97c8e996-b3f1-4b24-b85a-cd6e30eb9cb5 Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Pfammatter, T. (Thomas)|||/items/c83b27c3-39b1-4a15-825e-c36159a6fedf Arnold, D. (Dirk)|||/items/099bd9e3-21b5-4667-b221-019be2f28370 Cianni, R. (Roberto)|||/items/44136911-1445-4958-bb06-51b0c81a263a Maleux, G. (Geert)|||/items/f9cabf53-a062-4f9b-8099-301cdb26555e Munneke, G. (Graham)|||/items/33afac81-9bd0-4391-b00c-2ab2a29e2103 Pellerin, O. (Olivier)|||/items/bd7ccdfa-8f2e-419e-bcc0-9e87ccde316e Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Schaefer, N. (Niklaus)|||/items/e3405054-aec1-45e4-8aed-64763da49bc9 Jong, N. (Niels) de|||/items/c5c5d9da-4d8e-45f7-814b-52a5924df343 Bilbao, J.I. (José I.)|||/items/bd708ce9-03bf-41e5-96f2-0d6ce8b6fe88 Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90 Purpose: To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). Materials and methods: Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected. Results: Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE. Conclusion: In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. Level of evidence: Level 3. Trial registration: ClinicalTrials.gov NCT02305459. Springer Nature https://hdl.handle.net/10171/115041 |
| spellingShingle | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) Helmberger, T. (Thomas)|||/items/f9fa8d53-650f-41f2-9eaa-a0b2de5d4e93 Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90 |
| title | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) |
| title_full | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) |
| title_fullStr | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) |
| title_full_unstemmed | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) |
| title_short | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) |
| title_sort | Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: First results from the prospective multicentre observational study Cirse Registry for Sir-spheres Therapy (CIRT) |
| topic | Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90 |
| topic_facet | Hepatocellular carcinoma Liver Metastasis Observational study Radioisotope brachytherapy Registries Therapeutic embolization Trans-arterial radioembolization Yttrium-90 |
| url | https://hdl.handle.net/10171/115041 |